Sponsors

New blood test to help guide prostate cancer treatment decisions

A blood test could help identify men with advanced prostate cancer who are more likely to experience longer disease control following targeted radiotherapy, according to new research.

New analysis from the TRAP trial found that measuring circulating tumour DNA (ctDNA) in the blood before treatment could provide additional information about how a patient's cancer may respond to radiotherapy. The research, led by The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London and University College London, has been published in International Journal of Radiation Oncology - Biology – Physics.

CtDNA consists of small fragments of genetic material released by cancer cells into the bloodstream. Analysing these fragments can help researchers detect signs of cancer activity that are not apparent on scans.

Sponsored by The Royal Marsden NHS Foundation Trust, the TRAP trial investigated the use of stereotactic body radiotherapy (SBRT) in patients with hormone-resistant oligoprogressive prostate cancer. Oligoprogressive cancer occurs when cells from the original tumour travel within the body but are only active at fewer than three sites, forming new tumours or lesions. The men on the trial received radiotherapy to these areas while continuing their existing hormone therapies, such as abiraterone or enzalutamide.

However, cancer may also be growing in areas too small to be detected by scans, and not all patients experience the same duration of cancer control following radiotherapy. A blood test could help researchers better understand these differences and investigate which patients may be most suitable for this treatment.

Stereotactic body radiotherapy (SBRT) is an advanced form of radiotherapy that delivers highly focused radiation to tumours. In men whose prostate cancer is progressing at a small number of areas, it can target these sites while allowing them to continue their existing hormone-based treatment. 

The research team analysed blood samples collected before radiotherapy from 77 men participating in the TRAP trial. The patients were monitored for more than two years. Of these men, 19 had detectable ctDNA before radiotherapy, while 58 had no detectable ctDNA.

Men with no detectable ctDNA experienced significantly longer progression-free survival following radiotherapy than those with detectable ctDNA. Median time without disease progression was 7.8 months for men with no detectable ctDNA, compared with three months for those with detectable ctDNA.

Six months after treatment, around 58% of men whose blood samples were negative for ctDNA remained free from disease progression, compared with 21% of men who tested positive. The association remained significant after the researchers accounted for other clinical factors, including age, prostate-specific antigen (PSA) levels, previous chemotherapy and the location of the treated tumour. The findings could help inform future studies investigating whether ctDNA testing can guide treatment decisions for men with advanced prostate cancer.

Men with no detectable ctDNA may be more likely to experience longer disease control after radiotherapy to the visible areas of progression. In contrast, detectable ctDNA could indicate that cancer remains active elsewhere in the body, potentially helping researchers investigate when alternative treatment may be needed.

By combining blood-test results with imaging and other clinical information, researchers hope to develop a clearer understanding of how advanced prostate cancer progresses and how best to tailor treatment to individual patients.

Professor Alison Tree, Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust, Honorary Reader at The Institute of Cancer Research and Chief Investigator of the TRAP trial, said: “These findings suggest that a simple blood test could give us valuable additional information about how advanced prostate cancer is behaving, beyond what we can see on scans. We found that men with no detectable ctDNA before radiotherapy tended to have longer periods without their cancer progressing than those with detectable levels.

“Although more research is needed before this test can be used to guide treatment decisions, our findings are an important step towards understanding which patients may benefit most from targeted radiotherapy and how we could better personalise treatment for men with advanced prostate cancer.”

  • Patel P, Dreibe S, Attard G, et al. Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-Suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial. Int J Radiat Oncol Biol Phys. 2026;125(1):285-294. doi:10.1016/j.ijrobp.2025.02.046

 

Latest Issues

DIA-MHRA Global Summit

Senate House, Malet Street, London, WC1E 7HU
16-17 November, 2026

UK NEQAS for Microbiology & Parasitology Annual Scientific Meeting 2026

The Royal National Hotel, 38 – 51 Bedford Way, London, WC1H 0DG
27 November, 2026

UK NEQAS webinar: Epigenetics

Online
1 December, 2026

Weqas Annual POCT Conference 2026

London, Venue - TBC
8-9 December, 2026

UK NEQAS webinar: Fresh Muscle Biopsies

Online
8 December, 2026